DK2187878T3 - Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer - Google Patents

Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer

Info

Publication number
DK2187878T3
DK2187878T3 DK08838691.7T DK08838691T DK2187878T3 DK 2187878 T3 DK2187878 T3 DK 2187878T3 DK 08838691 T DK08838691 T DK 08838691T DK 2187878 T3 DK2187878 T3 DK 2187878T3
Authority
DK
Denmark
Prior art keywords
hemangiomas
blocker
medicament
beta
manufacture
Prior art date
Application number
DK08838691.7T
Other languages
English (en)
Inventor
Christine Leaute-Labreze
De La Roque Eric Dumas
Alain Taieb
Jean-Benoit Thambo
Original Assignee
Univ Bordeaux Segalen
Ct Hospitalier Universitaire De Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2187878(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Bordeaux Segalen, Ct Hospitalier Universitaire De Bordeaux filed Critical Univ Bordeaux Segalen
Application granted granted Critical
Publication of DK2187878T3 publication Critical patent/DK2187878T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
DK08838691.7T 2007-10-19 2008-10-16 Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer DK2187878T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291273A EP2050441A1 (en) 2007-10-19 2007-10-19 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US98950707P 2007-11-21 2007-11-21
PCT/IB2008/002746 WO2009050567A2 (en) 2007-10-19 2008-10-16 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Publications (1)

Publication Number Publication Date
DK2187878T3 true DK2187878T3 (da) 2011-09-19

Family

ID=39156667

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08838691.7T DK2187878T3 (da) 2007-10-19 2008-10-16 Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer
DK09015563.1T DK2233135T3 (da) 2007-10-19 2008-10-16 Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09015563.1T DK2233135T3 (da) 2007-10-19 2008-10-16 Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer

Country Status (31)

Country Link
US (2) US8338489B2 (da)
EP (3) EP2050441A1 (da)
JP (1) JP5552700B2 (da)
KR (2) KR101562627B1 (da)
CN (2) CN103169971A (da)
AR (1) AR068927A1 (da)
AT (1) ATE512661T1 (da)
AU (1) AU2008313405B2 (da)
BR (1) BRPI0816536A2 (da)
CA (1) CA2701953C (da)
CL (1) CL2008003083A1 (da)
CO (1) CO6270209A2 (da)
CY (1) CY1112604T1 (da)
DE (1) DE08838691T1 (da)
DK (2) DK2187878T3 (da)
ES (2) ES2390534T3 (da)
HK (1) HK1148940A1 (da)
HR (2) HRP20110659T1 (da)
IL (1) IL205129A (da)
MA (1) MA31843B1 (da)
MX (1) MX2010004295A (da)
MY (1) MY156750A (da)
NZ (1) NZ584307A (da)
PA (1) PA8799401A1 (da)
PL (2) PL2187878T3 (da)
PT (2) PT2233135E (da)
RU (1) RU2471500C2 (da)
SI (2) SI2187878T1 (da)
TN (1) TN2010000170A1 (da)
TW (1) TWI531365B (da)
WO (1) WO2009050567A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US8633181B2 (en) * 2009-04-09 2014-01-21 Rutgers, The State University Of New Jersey Treatment of cutaneous hemangioma
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
WO2012125413A2 (en) * 2011-03-12 2012-09-20 Vicus Therapeutics, Llc Compositions for ameliorating systemic inflammation and methods for making and using them
CN102579412A (zh) * 2012-02-16 2012-07-18 山东省立医院 一种治疗婴幼儿血管瘤的外用药物及其制备方法
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
CN103054793B (zh) * 2013-01-05 2015-01-21 广州军区广州总医院 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN104274390B (zh) * 2014-09-04 2017-06-13 郑家伟 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用
RU2584082C1 (ru) * 2015-01-21 2016-05-20 Ильдар Наилевич Нурмеев Способ лечения гемангиом
CN105434337B (zh) * 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途
CN105106105A (zh) * 2015-08-14 2015-12-02 天津市聚星康华医药科技有限公司 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法
US20170360829A1 (en) * 2016-01-27 2017-12-21 Gillies Mcindoe Research Institute Treatment of vascular anomalies
RU2617516C1 (ru) * 2016-03-24 2017-04-25 Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт неотложной детской хирургии и травматологии Департамента здравоохранения города Москвы Способ лечения младенческих гемангиом
CN106474061B (zh) * 2016-12-08 2019-01-22 黑龙江童医生儿童生物制药有限公司 一种盐酸普萘洛尔口服乳剂及其制备方法
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
EA202090452A1 (ru) 2017-08-07 2020-06-15 Консехо Супериор Де Инвестигасионес Сьентификас Соединения для лечения болезни фон гиппеля-линдау
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
CN110314154A (zh) * 2018-03-28 2019-10-11 武汉恒信源药业有限公司 左旋普萘洛尔在制备治疗血管病变药物中的应用
US20210346319A1 (en) * 2018-10-04 2021-11-11 Emory University Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto
RU2701213C1 (ru) * 2018-12-27 2019-09-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения инфантильных гемангиом
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
CA3139865A1 (en) * 2019-05-24 2020-12-03 Pediatric Derm Developement Llc Treatment of infantile hemangioma
CN111773226A (zh) * 2019-06-26 2020-10-16 首都医科大学附属北京儿童医院 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途
JP2023512252A (ja) * 2020-01-29 2023-03-24 ギリーズ マキンドー リサーチ インスティテュート 血管腫の治療のための方法および組成物
JP2023533911A (ja) * 2020-07-10 2023-08-07 チャン グァン メモリアル ホスピタル，リンコウ 上皮成長因子受容体阻害剤によって誘発される上皮細胞損傷を軽減し及び癌細胞を阻害する組成物の製造のための、β－１アドレナリン受容体アンタゴニストの使用
US20230364242A1 (en) * 2020-09-30 2023-11-16 Nissan Chemical Corporation Water-soluble complex containing beta blocker and lecithin
CN113274348A (zh) * 2021-06-11 2021-08-20 四川大学华西医院 用于治疗婴幼儿血管瘤的阿替洛尔凝胶、制备方法及应用
PL244294B1 (pl) * 2022-09-20 2024-01-03 Univ Medyczny W Lodzi Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301580A (da) 1962-12-11
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
GB1253709A (en) 1968-05-22 1971-11-17 Frosst & Co Charles E Thiadiazole derivatives
US3657237A (en) 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
SE354851B (da) 1970-02-18 1973-03-26 Haessle Ab
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
DE69435002T2 (de) * 1993-07-19 2008-03-20 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene Mittel enthaltend Taxol und einen nicht biodegradierbaren Träger und deren Verwendung
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
IL126837A0 (en) * 1996-05-01 1999-09-22 Lilly Co Eli Therapeutic treatment for vegf related diseases
GB9616672D0 (en) * 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
US7459470B2 (en) 2001-05-08 2008-12-02 Schering Ag N-oxide anthranylamide derivatives and their use as medicaments
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CA2576255A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Also Published As

Publication number Publication date
IL205129A (en) 2015-05-31
PL2187878T3 (pl) 2012-01-31
AU2008313405A1 (en) 2009-04-23
CN102006864B (zh) 2013-01-16
US20130072551A1 (en) 2013-03-21
CO6270209A2 (es) 2011-04-20
PT2233135E (pt) 2012-09-06
ES2390534T3 (es) 2012-11-13
CA2701953C (en) 2015-05-19
WO2009050567A2 (en) 2009-04-23
EP2233135A1 (en) 2010-09-29
IL205129A0 (en) 2010-11-30
US9173858B2 (en) 2015-11-03
EP2050441A1 (en) 2009-04-22
EP2187878B1 (en) 2011-06-15
CN103169971A (zh) 2013-06-26
CY1112604T1 (el) 2016-02-10
DE08838691T1 (de) 2010-08-26
US8338489B2 (en) 2012-12-25
MX2010004295A (es) 2010-08-02
ATE512661T1 (de) 2011-07-15
NZ584307A (en) 2012-03-30
SI2233135T1 (sl) 2012-10-30
EP2187878A2 (en) 2010-05-26
JP5552700B2 (ja) 2014-07-16
DK2233135T3 (da) 2012-10-01
HRP20120765T1 (hr) 2012-10-31
SI2187878T1 (sl) 2011-10-28
EP2233135B1 (en) 2012-06-27
AU2008313405B2 (en) 2013-12-19
CL2008003083A1 (es) 2009-03-06
JP2011500661A (ja) 2011-01-06
PA8799401A1 (es) 2009-05-15
HRP20110659T1 (hr) 2011-10-31
MA31843B1 (fr) 2010-11-01
PL2233135T3 (pl) 2012-11-30
RU2471500C2 (ru) 2013-01-10
TWI531365B (zh) 2016-05-01
TW200932207A (en) 2009-08-01
TN2010000170A1 (en) 2011-11-11
US20100273889A1 (en) 2010-10-28
CA2701953A1 (en) 2009-04-23
WO2009050567A3 (en) 2009-06-18
CN102006864A (zh) 2011-04-06
ES2368299T3 (es) 2011-11-16
AR068927A1 (es) 2009-12-16
BRPI0816536A2 (pt) 2017-06-06
KR20150110827A (ko) 2015-10-02
PT2187878E (pt) 2011-09-07
EP2233135B8 (en) 2013-07-10
HK1148940A1 (en) 2011-09-23
RU2010112816A (ru) 2011-11-27
KR101562627B1 (ko) 2015-10-22
MY156750A (en) 2016-03-31
KR20100087012A (ko) 2010-08-02

Similar Documents

Publication Publication Date Title
DK2187878T3 (da) Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer
CY2018004I1 (el) Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
BRPI0819073A2 (pt) fralda descartável
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2073860T3 (da) Lægemiddelfrigivende coatinger til medicinske indretninger
DK2452281T3 (da) Fremgangsmåde til at forudsige virkningen af lægemidler i en patient
DK2173407T3 (da) Anordning til indgivelse af lægemiddel
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
BRPI0813546A2 (pt) interface ortopédica
DK2018206T3 (da) Bandage til medicinsk anvendelse
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2035369T3 (da) Terapeutiske
BRPI0819071A2 (pt) fralda descartável
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2173831T3 (da) Brøndbehandling
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
DK2033675T3 (da) Inhalationsapparat
DK2131818T3 (da) Ny doseringsform
BRPI0818598A2 (pt) agentes terapêuticos - 802
DK2129422T3 (da) Doseringsinhalator
BRPI0814248A2 (pt) Inalador